Wait...
  1. Home >
  2. Export Import News >
  3. Economy News >
  4. Budget 2020: A look at pharma sector's wishlist for FM Nirmala Sitharaman >
  5. Budget 2020: A look at pharma sector's wishlist for FM Nirmala Sitharaman

Online Export Import Data Search

Recent Searches: No Recent Searches
Complete Training Video : Click Here

Budget 2020: A look at pharma sector's wishlist for FM Nirmala Sitharaman.


Date: 24-01-2020
Subject: Budget 2020: A look at pharma sector's wishlist for FM Nirmala Sitharaman
The Indian pharmaceutical industry expects the government to restore the tax benefit offered on research and development expenditure in the upcoming Union Budget.

The industry also hopes the government will announce incentives in the budget to encourage setting up bulk drug manufacturing units in the country, in addition to scale-up of spending on healthcare.

"India must move from predominantly branded generic drugs to discovering and developing new drugs; for that the government should resume tax exemption of 200 percent on R&D,” said Sudarshan Jain, Secretary General of Indian Pharmaceutical Alliance (IPA), the industry body that represents large domestic pharmaceutical companies.

Jain sought government to announce incentives to set up 4-6 bulk drug clusters across India to reduce dependence on import. He also sought government to set up innovation clusters.

Indian pharmaceutical industry imports almost 80 percent of its raw materials from China, exposing Indian industry to vagaries of prices hikes and shortages, the government is also worried about drug security, especially antibiotics in cases of emergencies like natural calamities and wars.

The government had introduced a weighted tax deduction of 200 percent on company expenditure on in-house research and development (R&D) in the 2010 Budget, in order to boost innovation in the country. In weighted tax deduction, double the amount spent on R&D is deducted from the profit of the company providing them additional cash to invest in R&D.

While the tax incentive isn't specific to the pharma industry, but pharmaceutical companies have been major beneficiaries as they have increased their average R&D spend from 5.3 percent of revenue in FY12 to 8.5 percent in FY19.

However, the 200 percent weighted deduction on R&D was short-lived, with the government in 2016 Budget cutting it to 150 percent from 2017 onwards and to 100 percent from 2020 onwards.

To allay industry concerns the government in the same budget announced a patent box-type of incentives for the first time, wherein income received by Indian companies in the form of royalties and technology license fees would be taxed at a reduced rate of 10 percent from the fiscal year 2016–2017 onwards.

The government said this move was designed to stimulate innovation by raising the revenue that companies could earn from their intellectual property.

The industry now wants taxes to eliminated on royalties and technology license fees it earns.

To give fillip to exports - IPA said the government should announce a new scheme of export incentives or subsidies in place of the now scrapped Merchandise Exports from India Scheme (MEIS) to promote pharmaceutical exports.

Under the Merchandise Exports from India Scheme (MEIS), the government provides duty benefits at different rates depending on product and country. The government had to scrap MEIS, as it wasn't compliant with WTO regulations. Pharma companies were major beneficiaries of the scheme. India's pharmaceutical exports rose 11 per cent to $19.2 billion in 2018-19.

The pharma and healthcare sectors have sought the Finance Minister to increase spend on healthcare in proportionate to GDP.

"The Indian Budget should focus on increasing public spending on healthcare, considering India’s demographics, growing population and increasing disease burden. The Budget of 2019-20 saw Rs 62,398 crore outlay for the healthcare sector which was just 1 percent of GDP. This should be increased to 2.5 percent or around Rs 150,000 crore to drive the health sector fast forward," said Dr. Azad Moopen-Founder Chairman & Managing Director, Aster DM Healthcare.

Moopen also stressed on the need for a viability gap funding by the government for investors who setup hospitals in smaller cities to increase the provider base for Ayushman Bharat and sought an increase of package rates of Ayushman Bharat for more hospitals.

Public sector investment on healthcare in India is one of the lowest globally, at 1.3 percent of GDP.

The budgetary outlay for the Ayushman Bharat the flagship health insurance scheme of the central government remains low (Rs. 6400 crore in BE 2019-20) vis-a-vis its funding requirement.

"Increase in the budgetary support to the scheme will help expand the network and the coverage, while providing affordable healthcare facilities to beneficiaries. The same is also expected to be positive for hospitals in Tier II and III cities and smaller towns, particularly for those that have low occupancies or those that are positioned for affordable care," rating agency ICRA said.

Source: moneycontrol.com

Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Both
 Buyers
 Suppliers
 Both
OR
 Exim Help
+


What is New?

Date: 08-02-2020
Notification No. 08/2020-Customs
Seeks to exempt specified goods from Health Cess imposed on the medical devices falling under heading 9018 to 9022 in terms of clause 139 of the Finance Bill, 2020.

Date: 06-02-2020
Notification No.11/2020 - Customs (N.T.)
Exchange Rates Notification No.11/2020-Custom (NT) dated 06.02.2020

Date: 03-02-2020
Notification No. 11/2020-Customs (N.T./CAA/EXTENSION/DRI)
Appointment of CAA by DGRI

Date: 03-02-2020
Notification No. 12/2020-Customs (N.T./CAA/DRI)
Appointment of CAA by DGRI

Date: 02-02-2020
Notification No. 06/2020 – Customs
Seeks to further amend notification No. 24/2005-Customs, dated the 1st March, 2005 so as to exclude copper and articles thereof from the exemption provided to raw materials use for manufacturing of ITA goods specified therein the notification

Date: 02-02-2020
Notification No. 07/2020 – Customs
Seeks to further amend notification No. 25/2005-Customs, dated the 1st March, 2005 so as to exclude copper and articles thereof from the exemption provided to raw materials use for manufacturing of ITA goods specified therein the notification.

Date: 02-02-2020
Notification No. 09/2020-Customs (N.T.)
Appointment of CAA by DGRI

Date: 02-02-2020
Notification No. 09/2020-Customs (N.T.)
Seeks to further amend Customs Tariff (Identification, Assessment and Collection of Anti-dumping Duty on Dumped Articles and for Determination of Injury) Rules, 1995 to change the anti-circumvention provision and make certain other miscellaneous changes.

Date: 02-02-2020
Notification No.10/2020-Customs (N.T.)
Seeks to further amend Customs Tariff (Identification, Assessment and Collection of Countervailing Duty on Subsidised Articles and for Determination of Injury) Rules, 1995 to introduce anti-circumvention provisions in these rules and make certain other miscellaneous changes.

Date: 02-02-2020
Notification No. 08/2020-Customs
Seeks to exempt specified goods from Health Cess imposed on the medical devices falling under heading 9018 to 9022 in terms of clause 139 of the Finance Bill, 2020.



Exim Guru Copyright © 1999-2020 Exim Guru. All Rights Reserved.
The information presented on the site is believed to be accurate. However, InfodriveIndia takes no legal responsibilities for the validity of the information.
Please read our Terms of Use and Privacy Policy before you use this Export Import Data Directory.

EximGuru.com

C/o InfodriveIndia Pvt Ltd
F-19, Pocket F, Okhla Phase-I
Okhla Industrial Area
New Delhi - 110020, India
Phone : 011 - 40703001